Background Variants at the oculocutaneous albinism 2 (OCA2)/HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) locus have been associated with pigmentation phenotypes and risk of developing several types of skin cancer. Objectives To evaluate OCA2/HERC2 locus variants for their impact on time to develop cutaneous squamous cell carcinoma (cSCC) in organ transplant recipients (OTRs) who are at elevated risk of developing cSCC. Methods Participants were solid OTRs ascertained from two centres (n = 125 and 261) with an average of 13Á1 years of follow-up post-transplant. DNA was available for genotyping for all participants, in addition to medical records and questionnaire data. The Ohio State University study had a case-control design with prospective follow-up, and the University of California San Francisco study was a national cross-sectional survey with retrospective chart review. Results OCA2 variants rs12913832 and rs916977 were significantly associated with time to first cSCC post-transplant. OTRs homozygous for the brown-eye alleles of rs916977 (GG) and rs12913832 (AA) had significant delays of time to first cSCC post-transplant compared with individuals homozygous for the blue-eye alleles (hazard ratio 0Á34, P < 0Á001 and hazard ratio 0Á54, P = 0Á012, respectively). Both variants were highly associated with eye colour in the combined studies (P < 0Á001). Conclusions This study is the first to show an association between OCA2/HERC2 variants and time to first cSCC post-transplant. This may impact dermatological screening recommendations for high-risk populations.
Summary
Background Variants at the oculocutaneous albinism 2 (OCA2)/HECT and RLD domain containing E3 ubiquitin protein ligase 2 (HERC2) locus have been associated with pigmentation phenotypes and risk of developing several types of skin cancer. Objectives To evaluate OCA2/HERC2 locus variants for their impact on time to develop cutaneous squamous cell carcinoma (cSCC) in organ transplant recipients (OTRs) who are at elevated risk of developing cSCC. Methods Participants were solid OTRs ascertained from two centres (n = 125 and 261) with an average of 13Á1 years of follow-up post-transplant. DNA was available for genotyping for all participants, in addition to medical records and questionnaire data. The Ohio State University study had a case-control design with prospective follow-up, and the University of California San Francisco study was a national cross-sectional survey with retrospective chart review. Results OCA2 variants rs12913832 and rs916977 were significantly associated with time to first cSCC post-transplant. OTRs homozygous for the brown-eye alleles of rs916977 (GG) and rs12913832 (AA) had significant delays of time to first cSCC post-transplant compared with individuals homozygous for the blue-eye alleles (hazard ratio 0Á34, P < 0Á001 and hazard ratio 0Á54, P = 0Á012, respectively). Both variants were highly associated with eye colour in the combined studies (P < 0Á001). Conclusions This study is the first to show an association between OCA2/HERC2 variants and time to first cSCC post-transplant. This may impact dermatological screening recommendations for high-risk populations.
What's already known about this topic?
• Variants in pigment-related genes have been found to be associated with increased risk of skin cancer through both candidate gene and genome-wide association studies.
• Blue-eye-associated alleles at the HERC2/OCA2 locus have associated with increased risk of cutaneous squamous cell carcinoma (cSCC) in immunocompetent populations in candidate gene and genome-wide association studies.
What does this study add?
• This study shows that blue-eye-associated variants of rs12913832 and rs916977, at the HERC2/OCA2 locus, are associated with decreased time to first cSCC post-transplant in solid organ transplant recipients.
What is the translational message?
• These results have potential implications for the development of screening recommendations and risk models for cSCC in organ transplant recipients.
Over 700 000 cutaneous squamous cell carcinomas (cSCCs) are treated each year in the U.S.A. 1 Risk factors for cSCC include ageing, fair skin, extensive sun exposure and immunosuppression. [2] [3] [4] In part due to being immunosuppressed, solid organ transplant recipients (OTRs) have an estimated 60-200-fold increased risk of developing cSCC, and increased mortality due to cSCC of 4Á94 per 100 000 person years. [5] [6] [7] [8] Studies also indicate a genetic component to the disease, with heritability studies for cSCC giving a prevalence ranging from 8% to 43%.
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Different approaches have been employed to identify putative risk alleles. These include mouse models of linkage, candidate gene-based case-control studies, and, more recently, genome-wide association studies (GWASs). The murine skin tumour susceptibility 1 (Skts1) locus on chromosome 7 was first identified in 1995 and has been identified in multiple subsequent linkage studies of susceptibility to chemically induced skin cancer using various crosses of skin cancer-susceptible and skin cancer-resistant mice. [12] [13] [14] [15] One of the genes mapping within the peak linkage region for Skts1 is Oca2, also known in mouse as the pink-eyed dilution gene. Oculocutaneous albinism (OCA)2, a protein related to 12-transmembrane-domain transporters, is known to be important in melanin synthesis, likely through trafficking of melanosomes and processing and aiding in the cellular localization of tyrosinase. Pathogenic mutations in OCA2 are associated with oculocutaneous albinism type II. Variants at this locus have been associated with eye colour, skin pigment and/or risk of skin cancer. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] Variant rs12913832, which maps in the neighbouring HERC2 gene, has been strongly associated with blue eye colour in multiple studies and may account for up to 50% of the variance in eye colour. [20] [21] [22] The blue-eye allele at rs12919382 leads to decreased expression of OCA2 by disrupting an enhancer site. 23 Other variants in HERC2, such as rs916977, have also been strongly associated with eye colour. 20 There have been multiple studies linking variants in or near OCA2 with skin cancer risk. [24] [25] [26] [27] [28] [29] [30] A GWAS identified two OCA2/HERC2 variants, rs1129038 and rs12913832, as strongly associated with both melanoma risk and pigmentary traits. 21 In Japanese populations, the OCA2 H615R variant was associated with melanoma risk and the A481T variant was associated with cSCC and actinic keratosis. 30 An R419Q variant in OCA2 was associated with an odds ratio of 1Á50 for basal cell carcinoma and cSCC in a GWAS. 25, 29 Two recent GWASs for cSCC found multiple variants, including novel variants not previously linked to pigmentation or skin cancer, at the OCA2/HERC2 locus that were associated with an increase in the risk of cSCC independently of their estimated impacts on pigmentation. 28, 29 One previous study looked at the OCA2/HERC2
variants rs916977 and rs12916300 in OTRs and did not see an association with cSCC risk; however, it was underpowered to identify an effect of the same magnitude observed in the GWAS. 31 Importantly, several models to predict cSCC in OTRs incorporate eye colour (blue, hazel or green) as a risk variable. 32, 33 Only a few studies have specifically evaluated OCA2/HERC2 locus variants for cSCC risk, and these have shown association between multiple OCA2/HERC2 locus variants and cSCC risk. [28] [29] [30] [31] Based on the data from both mouse and human, we hypothesized that variants at the human equivalent of Skts1, specifically those mapping to the OCA2/HERC2 locus, would be associated with time to cSCC in OTRs, a population at elevated risk for cSCC. The specific goal of this study was to determine whether two OCA2/HERC2 variants, rs916977 and rs12913832, which are both strongly associated with eye colour and pigmentation, were associated with time to first cSCC in the OTRs. These variants were chosen for study as they are frequently linked to eye colour, skin pigment and skin cancer, and functional data link rs12913832 with expression of OCA2.
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Patients and methods
Study participants
Human studies were approved by the Ohio State University (OSU) cancer institutional review board (approval #2005C0069) and the University of California San Francisco (UCSF) institutional review board (approval #10-02517). All study participants provided informed consent for these studies. The two study populations were genotyped for the OCA2/ HERC2 variants (Table 1 ). Blood or mouthwash samples were used as a source of normal genomic DNA; no differences were noted in genotyping quality between the DNA sources.
Criteria for the study included being a solid OTR with ≥ 5 years of follow-up post-transplant. The OSU 'high-risk' study consisted of 125 OTRs who were ascertained between 2005 and 2012: 67 with a diagnosis of at least one cSCC (cases) and 59 individuals who did not develop cSCC, with an average of 12Á1 years of follow-up (controls). 34, 35 Eligibility criteria included having a solid organ transplant, being able to provide a DNA sample, completion of a questionnaire, and release of medical records. Cases were enriched for 'high-risk' individuals with more than one cSCC post-transplant, and controls were those who did not have a cSCC before or within the time of follow-up. Although individuals in the OSU study were initially ascertained retrospectively after transplant, medical records were reviewed on an annual basis after enrolment for the study; multiple individuals originally ascertained in the OSU 'control' group developed cSCC and were subsequently considered as cases. All cSCC diagnoses were confirmed by pathology reports, and lack of cSCC diagnosis was confirmed through medical records.
The UCSF organ transplant study was a cross-sectional study with retrospective chart review drawing from transplant recipients across the U.S.A. collected between 2004 and 2008. 36 This study included 192 OTRs who developed a cSCC confirmed by medical records. 'Controls' consisted of 71 OTRs who did not develop cSCC in the same post-transplant period, with an average follow-up of 9Á5 years. 31, [34] [35] [36] Eligibility included release of medical records, including pathology reports for cSCC diagnosis, completion of a questionnaire and DNA availability for genotyping. Eye colour and skin type for participants of both studies were determined through selfreported answers on the questionnaire.
Variants for study and genotyping
The OCA2/HERC2 locus was initially chosen for study because it is orthologous to a skin cancer susceptibility locus, Skts1, in mouse. [12] [13] [14] [15] We considered all variants at this locus previously shown to be associated with skin cancer, eye colour and/or pigment for inclusion in this study. Variants rs916977 and rs12913832 were chosen for evaluation as they are frequently linked to eye colour, skin pigment and skin cancer, and they had minor allele frequencies > 15% in non-Hispanic white individuals. 37 Variant rs12913832 was selected as it had the strongest association with eye colour at this locus, is associated with decreased melanin production, and shows functional enhancer activity. 20, 22, 23, 38, 39 Variant rs916977 showed the lowest P-value for risk in a cSCC study in non-Hispanic white patients. 40 Genotyping for the OSU and UCSF samples was performed using a QuantStudio OpenArray Real-Time PCR platform (Thermo Fisher Scientific Inc., Waltham, MA, U.S.A.). A preamplification step was used for all genotyping performed at OSU. All studies used the same Taqman SNP genotyping assays: C_2567831_10 for rs916977 and C_30724404_1 for -test or Fisher's exact test without missing data. Cox regression models were used to evaluate the effect of rs916977 alone, rs12913832 alone, and rs916977 and rs12913832 together on time to first cSCC post-transplant among the genotypes, adjusting for cohort, age, sex, race/ethnicity, transplant type and skin type. Race/ ethnicity and skin type (P > 0Á05) were sequentially removed from the Cox regression models. Fitzpatrick skin type and race/ethnicity were not significantly (all P > 0Á05) associated with time to first cSCC. Therefore, they were not included in the final Cox regression models. Hazard ratios (HRs) with 95% confidence intervals (CIs) were determined. Adjusted survival curves were provided for the combined study using the mean-of-covariates method. The Bonferroni method was used to adjust for multiple comparisons. P-values < 0Á05 were considered statistically significant. All statistical analyses were conducted using SAS for Windows version 9Á4 (SAS Institute Inc., Cary, NC, U.S.A.).
Results

Description of study participants
A comparison of the study participants between OSU and UCSF revealed multiple differences between the two cohorts ( Table 1) . These included the proportion of OTRs who developed a cSCC post-transplant, which was higher in the UCSF nationally accrued cohort than in the OSU cohort (P < 0Á001); a slightly younger median age at transplant (44 vs. 48 years) and age at first cSCC post-transplant (54 vs. 58 years) in the OSU cohort (P = 0Á013 and 0Á005, respectively); a higher proportion of heart/lung transplants in the UCSF cohort (P = 0Á005) and differences in eye colour distribution (P = 0Á002) and Fitzpatrick skin type (P = 0Á007). Despite the overall differences it is not clear whether these are due to differences in the proportion of cSCC cases or the overall population.
As cSCC is more frequent in men than in women, and more men receive transplants, 41 more male patients were accrued to the study for both cohorts (63Á2% male in the OSU cohort and 69Á0% in the UCSF cohort). In the combined study, 69Á5% of cases and 62Á2% of controls were male ( Table 2) . Cases of cSCC had a higher median age of transplant than controls (48 vs. 45 years; P = 0Á012), which is consistent with previous studies, suggesting that age at transplant is a risk factor for cSCC. 8, 32, 33, 36, 42 Cases had a higher proportion of blue-eyed individuals than controls (46Á7% vs. 36Á8%), but this was not significant (P = 0Á27). Other confounders that were significantly different between OTRs with and without cSCC diagnoses included race/ethnicity, Fitzpatrick skin type and transplant organ type (all P < 0Á001).
OCA2/HERC2 variants in the organ transplant recipient population
Because the risk of cSCC in OTRs is so high, we hypothesized that while the overall risk for cSCC may not be dependent on the HERC2/OCA2 variants, they may affect the time to first cSCC post-transplant. OTRs homozygous for the brown-eye alleles for rs916977 (GG) and rs12913832 (AA) did have significant delays before the first cSCC post-transplant compared with individuals homozygous for the blue-eye alleles using Cox regression models: HR 0Á34, 95% CI 0Á19-0Á62, P < 0Á001 and HR 0Á54, 95% CI 0Á33-0Á87, P = 0Á012, respectively (Fig. 1, Table 3 ). Using a Cox regression model, we estimated the time to first cSCC post-transplant for each genotype of rs916977 and rs12913832 (Fig. 1) . The estimated median time to first cSCC post-transplant was 26Á5 years for individuals homozygous for the rs916977 brown-eye allele vs. 14Á2 years for individuals homozygous for the rs916977 blue-eye allele (P < 0Á001). A similar finding was observed for rs12913832, with individuals having a median time to first cSCC post-transplant in the homozygous genotype groups of 21Á6 vs. 14Á2 years (P = 0Á012).
Considering that rs916977 and rs12913832 could be dependent, multivariate analysis with both single-nucleotide polymorphisms was studied using the Cox regression model, controlling for other important confounders. We found that OTRs homozygous for the brown-eye allele of rs916977 (GG) still had a significant delay of time to first cSCC post-transplant compared with individuals homozygous for the blue-eye allele (HR 0Á26, 95% CI 0Á11-0Á60, P = 0Á002; Table 3 ). However, carrying two brown-eye alleles for rs12913832 was not significantly associated with time to first cSCC post-transplant after adjusting for eye colour (HR 1Á42, 95% CI 0Á70-2Á91, P = 0Á33; Table 3 ).
Association between eye colour and OCA2/HERC2 variants
Previous studies suggest that rs12913832 contributes 50% of the variance of blue eye colour. 21 We determined whether rs916977 and rs12913832 were associated with the four categories of self-reported eye colour (blue, brown, green and hazel). As expected, rs12913832 genotypes strongly correlated with eye colour, with 73Á6% of individuals in both studies who were homozygous for the blue-eye allele having blue eyes, in contrast to only 2Á6% of individuals with brown eyes (P < 0Á001; Table 4 ). The rs916977 variant was also correlated with eye colour (P < 0Á001). Approximately 58% of individuals with blue eyes who were homozygous for the rs916977 blue-eye-associated allele had blue eyes (P < 0Á001), whereas 17% of individuals had brown eyes. To determine whether eye colour could potentially be used as a surrogate for genotype in assessing risk, we used logistic regression models to compare the overall risk of disease and time to first cSCC post-transplant among eye colour types adjusting for age, follow-up time, sex, cohort, race/ethnicity, transplant type and skin type. There were no significant differences in the risk of disease or time to first cSCC between eye colour groups.
Discussion
This study evaluated variants at the OCA2/HERC2 locus for association with time to cSCC in OTRs. This study is the first to show an association between OCA2/HERC2 and time to first cSCC post-transplant. This may have implications for dermatological recommendations for transplant recipients. Our findings do replicate studies showing a connection between rs916977 and rs12913832 and blue eye colour. 16, [21] [22] [23] However, although the rs12913832 variant shows associations with both blue eye colour and time to cSCC, blue eye colour was not significantly associated with cSCC risk. The lack of association between eye colour and cSCC risk may be due to a number of factors including small sample size and the high risk of cSCC in OTR populations when followed for long times. Future analyses with larger sample sizes and/or an evaluation of cSCC risk within a shorter time period (i.e. within 5 years of transplant) may be more likely to show associations.
An important strength of this study is that although there are considerable differences between the two OTR studies included in this analysis, the findings of a delayed time to first cSCC post-transplant with OCA2/HERC2 variants are similar.
This study has potential implications for the development of screening recommendations and risk models for cSCC in OTRs. Although OTRs are all at highly increased risk for cSCC over the general population, it is possible that individuals with two brown-eye alleles for rs916977 and/or rs12913832 might be able to undergo a less rigorous dermatological screening evaluation or longer time between evaluations. There are currently no consistent guidelines in the U.S.A. for skin cancer screening in OTRs; for example, the U.S. Preventative Services Task Force does not mention skin cancer screening in this population and feels the evidence is insufficient for the general population. 43 Consistently with this, many OTRs are not even given recommendations for regular dermatological evaluations; studies such as this one are important in helping to shape recommendations. Indeed, two risk-prediction models for skin cancer in OTRs include eye colour, but based on our study, it may be more informative to include OCA2/ HERC2 genotypes. 30, 31 It will be important to consider these genotypes and/or eye colour in more refined models for cSCC prediction in these populations to determine their utility in models of risk and screening guidelines. This study has some limitations. Firstly, although both independent studies showed robust effects of time to first cSCC post-transplant, the overall sample sizes were small. Thus, it will be important to replicate these findings in additional high-risk populations and ethnic groups. Secondly, this study assessed only two variants at this locus. Other OCA2/HERC2 variants have recently been associated with cSCC. 28, 29 It is not known whether there will be multiple independent variants at this locus that are important for time to first cSCC diagnosis in transplant recipients. This study utilized self-reported information for skin type and eye colour. Although self-reports for skin type are fairly accurate, with one study showing a 95% agreement in selfreport vs. an individual typography angle score to measure pigment, there was a trend to overestimate skin colour category and underestimate skin sensitivity to sunburn. 44 If individuals in our study had similar biases, this could result in a small number of individuals with a misclassified Fitzpatrick skin type score. However, previous studies assessing the correlation between self-reported eye colour and digital assessment of iris colour showed a high degree of correlation (Pearson score of 0Á89), suggesting that self-report of eye colour is fairly accurate. 45 There were some demographic differences between the cohorts that could impact the results. For example, there was a younger age at transplant in the controls (45 years) than in the cases (48 years; P = 0Á012). To decrease the impact of age of transplant on the results, which has been associated with cSCC risk, we adjusted for age at transplant in the analyses. We also adjusted for other potential confounders in our analyses including cohort, sex and transplant type. However, we did not adjust our study for type of immunosuppressive drug regimens, which is known to influence cSCC risk. Adjustment for these factors will require much larger studies.
In summary, we identified variants at the OCA2/HERC2 locus that are associated with time to first cSCC post-transplant. Further research is warranted to determine whether OCA2/HERC2 genotypes and/or eye colour should be incorporated into cSCC risk models for OTRs.
